Harry Palmin
2021
In 2021, Harry Palmin earned a total compensation of $556.8K as Chief Operating Officer and Chief Financial Officer at Opexa Therapeutics, a 4% increase compared to previous year.
Compensation breakdown
| Option Awards | $174,354 |
|---|---|
| Salary | $382,400 |
| Total | $556,754 |
Palmin received $382.4K in salary, accounting for 69% of the total pay in 2021.
Palmin also received $174.4K in option awards.
Rankings
In 2021, Harry Palmin's compensation ranked 10,481st out of 12,405 executives tracked by ExecPay. In other words, Palmin earned more than 15.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,481 out of 12,405 | 16th |
Division Manufacturing | 4,637 out of 5,494 | 16th |
Major group Chemicals And Allied Products | 2,082 out of 2,369 | 12th |
Industry group Drugs | 1,846 out of 2,090 | 12th |
Industry Pharmaceutical Preparations | 1,366 out of 1,537 | 11th |
Source: SEC filing on April 15, 2022.
Palmin's colleagues
We found two more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2021.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019